Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 289-304

  Leung Hagesteijn, Chungyee ^a   Erdmann, Natalie ^a   Cheung, Grace ^a   Keats, Jonathan J ^b   Stewart, A Keith ^c   Reece, Donna E ^a,d   Chung, Kim Chan ^a   Tiedemann, Rodger E ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN; PROTEASOME INHIBITOR; X BOX BINDING PROTEIN 1;

ARTICLE; B LYMPHOBLAST; CELL DIFFERENTIATION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MEDIATOR; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 84883625365     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.009     Document Type: Article

References (40)

1. Alexanian R., Delasalle K., Wang M., Thomas S., Weber D. Curability of multiple myeloma. Bone Marrow Res. 2012, 2012:916479.
2. Balsas P., Galán-Malo P., Marzo I., Naval J. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Leuk. Res. 2012, 36:212-218.
3. Calfon M., Zeng H., Urano F., Till J.H., Hubbard S.R., Harding H.P., Clark S.G., Ron D. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002, 415:92-96.
4. Carrasco D.R., Sukhdeo K., Protopopova M., Sinha R., Enos M., Carrasco D.E., Zheng M., Mani M., Henderson J., Pinkus G.S., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
5. Chapman M.A., Lawrence M.S., Keats J.J., Cibulskis K., Sougnez C., Schinzel A.C., Harview C.L., Brunet J.P., Ahmann G.J., Adli M., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
6. Chen S., Blank J.L., Peters T., Liu X.J., Rappoli D.M., Pickard M.D., Menon S., Yu J., Driscoll D.L., Lingaraj T., et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010, 70:4318-4326.
7. Davenport E.L., Moore H.E., Dunlop A.S., Sharp S.Y., Workman P., Morgan G.J., Davies F.E. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110:2641-2649.
8. de Wilt L.H., Jansen G., Assaraf Y.G., van Meerloo J., Cloos J., Schimmer A.D., Chan E.T., Kirk C.J., Peters G.J., Kruyt F.A. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem. Pharmacol. 2012, 83:207-217.
9. Elkabetz Y., Shapira I., Rabinovich E., Bar-Nun S. Distinct steps in dislocation of luminal endoplasmic reticulum-associated degradation substrates: roles of endoplamic reticulum-bound p97/Cdc48p and proteasome. J.Biol. Chem. 2004, 279:3980-3989.
10. Franke N.E., Niewerth D., Assaraf Y.G., van Meerloo J., Vojtekova K., van Zantwijk C.H., Zweegman S., Chan E.T., Kirk C.J., Geerke D.P., et al. Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2011.
11. Hu C.C., Dougan S.K., McGehee A.M., Love J.C., Ploegh H.L. XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells. EMBO J. 2009, 28:1624-1636.
12. Jourdan M., Caraux A., Caron G., Robert N., Fiol G., Rème T., Bolloré K., Vendrell J.P., Le Gallou S., Mourcin F., et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J.Immunol. 2011, 187:3931-3941.
13. Keats J.J., Chesi M., Egan J.B., Garbitt V.M., Palmer S.E., Braggio E., Van Wier S., Blackburn P.R., Baker A.S., Dispenzieri A., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
14. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 2008, 7:1013-1030.
15. Koong A.C., Chauhan V., Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol. Ther. 2006, 5:756-759.
16. Kotz J. Cancer stress tests. SciBX 2011, 4:1-2.
17. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 2003, 100:9946-9951.
18. Lichter D.I., Danaee H., Pickard M.D., Tayber O., Sintchak M., Shi H., Richardson P.G., Cavenagh J., Bladé J., Façon T., et al. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 2012, 120:4513-4516.
19. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 2008, 11:164-179.
20. Mulligan G., Mitsiades C., Bryant B., Zhan F., Chng W.J., Roels S., Koenig E., Fergus A., Huang Y., Richardson P., et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109:3177-3188.
21. Nutt S.L., Taubenheim N., Hasbold J., Corcoran L.M., Hodgkin P.D. The genetic network controlling plasma cell differentiation. Semin. Immunol. 2011, 23:341-349.
22. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
23. Oerlemans R., Franke N.E., Assaraf Y.G., Cloos J., van Zantwijk I., Berkers C.R., Scheffer G.L., Debipersad K., Vojtekova K., Lemos C., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
24. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., Morse H.C., Liu C., Schwartzberg P.L., Leonard W.J. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
25. Papandreou I., Denko N.C., Olson M., Van Melckebeke H., Lust S., Tam A., Solow-Cordero D.E., Bouley D.M., Offner F., Niwa M., Koong A.C. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011, 117:1311-1314.
26. Pérez-Galán P., Mora-Jensen H., Weniger M.A., Shaffer A.L., Rizzatti E.G., Chapman C.M., Mo C.C., Stennett L.S., Rader C., Liu P., et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011, 117:542-552.
27. Politou M., Karadimitris A., Terpos E., Kotsianidis I., Apperley J.F., Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk. Res. 2006, 30:240-241.
28. Reimold A.M., Iwakoshi N.N., Manis J., Vallabhajosyula P., Szomolanyi-Tsuda E., Gravallese E.M., Friend D., Grusby M.J., Alt F., Glimcher L.H. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001, 412:300-307.
29. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N.Engl. J. Med. 2005, 352:2487-2498. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.
30. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
31. Rückrich T., Kraus M., Gogel J., Beck A., Ovaa H., Verdoes M., Overkleeft H.S., Kalbacher H., Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 2009, 23:1098-1105.
32. Shaffer A.L., Shapiro-Shelef M., Iwakoshi N.N., Lee A.H., Qian S.B., Zhao H., Yu X., Yang L., Tan B.K., Rosenwald A., et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004, 21:81-93.
33. Shaffer A.L., Wright G., Yang L., Powell J., Ngo V., Lamy L., Lam L.T., Davis R.E., Staudt L.M. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol. Rev. 2006, 210:67-85.
34. Shapiro-Shelef M., Lin K.I., McHeyzer-Williams L.J., Liao J., McHeyzer-Williams M.G., Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003, 19:607-620.
35. Siegel D.S., Martin T., Wang M., Vij R., Jakubowiak A.J., Lonial S., Trudel S., Kukreti V., Bahlis N., Alsina M., et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120:2817-2825.
36. Tiedemann R.E., Zhu Y.X., Schmidt J., Yin H., Shi C.X., Que Q., Basu G., Azorsa D., Perkins L.M., Braggio E., et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010, 115:1594-1604.
37. Tiedemann R.E., Zhu Y.X., Schmidt J., Shi C.X., Sereduk C., Yin H., Mousses S., Stewart A.K. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 2012, 72:757-768.
38. Wang L., Kumar S., Fridley B.L., Kalari K.R., Moon I., Pelleymounter L.L., Hildebrandt M.A., Batzler A., Eckloff B.W., Wieben E.D., Greipp P.R. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin. Cancer Res. 2008, 14:3503-3513.
39. Zhu K., Dunner K., McConkey D.J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2010, 29:451-462.
40. Zhu Y.X., Tiedemann R., Shi C.X., Yin H., Schmidt J.E., Bruins L.A., Keats J.J., Braggio E., Sereduk C., Mousses S., Stewart A.K. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011, 117:3847-3857.